# Immunotherapy to prevent drug-resistant tuberculosis

> **NIH NIH R01** · SEATTLE CHILDREN'S HOSPITAL · 2020 · $1,804,739

## Abstract

Project Summary / Abstract
Mycobacterium tuberculosis (Mtb) resistant to current first-line antibacterial agents is a serious and growing
public health threat, causing nearly 500,000 new tuberculosis (TB) cases and 170,000 deaths annually.
Treatments for drug-sensitive disease are lengthy, complex, and patient noncompliance exacerbates the
development of drug-resistant (DR) TB cases, for which treatments are even more prolonged, toxic, expensive,
and have lower cure rates.
The current proposal is designed to develop an innovative combination regimen using an existing second line
drug, Capreomycin, a new class of superior bactericidal antibiotic, Sutezolid, and a candidate therapeutic
vaccine delivered as an inhaled product that offers significant potential to improve treatment of DR-TB. An
effective treatment that targets both the pathogen and boosts the host immune response to accelerate
bacterial clearance, prevent relapse, and shorten therapy, would play an important role in dramatically
reducing the impact of the Mtb pathogen. We will leverage the strength of proprietary vaccine adjuvants, and a
clinical stage vaccine antigen, ID93, that has entered Phase 2 human clinical testing. This application is an
extension of our systematic and methodical approach towards controlling TB. Over the last twenty years, we
have applied this strategy towards developing viable vaccine candidates such as M72/AS01E and ID93/GLA-
SE (both in clinical stage testing). At present, to our knowledge, ID93/GLA-SE is the sole TB vaccine candidate
in the pipeline that has been tested for efficacy against DR-TB, as well as for prophylaxis and therapy in
multiple animal models of TB. Funding this R01 project to develop a candidate therapeutic vaccine used as
adjunctive treatment with drugs for DR-TB will address this global infectious disease threat.

## Key facts

- **NIH application ID:** 10079387
- **Project number:** 7R01AI125160-05
- **Recipient organization:** SEATTLE CHILDREN'S HOSPITAL
- **Principal Investigator:** Susan Louise Baldwin
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $1,804,739
- **Award type:** 7
- **Project period:** 2016-05-01 → 2022-11-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10079387

## Citation

> US National Institutes of Health, RePORTER application 10079387, Immunotherapy to prevent drug-resistant tuberculosis (7R01AI125160-05). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10079387. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*